NRXP – nrx pharmaceuticals, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

NRXP

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

1/2

08:03 am

nrxp

Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics

High Report

Report

12/31

08:22 am

nrxp

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.

High Report

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.

Report

12/30

08:11 am

nrxp

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression [Yahoo! Finance]

Low Report

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression [Yahoo! Finance]

Report

12/30

08:03 am

nrxp

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression

Medium Report

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression

Report

12/2

08:06 am

nrxp

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) had its price target raised by analysts at Ascendiant Capital Markets from $44.00 to $45.00. They now have a "buy" rating on the stock.

Medium Report

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) had its price target raised by analysts at Ascendiant Capital Markets from $44.00 to $45.00. They now have a "buy" rating on the stock.

Report

11/27

01:17 pm

nrxp

NRx Pharmaceuticals (NRXP) Upgraded to Buy: Here's Why [Yahoo! Finance]

Low Report

NRx Pharmaceuticals (NRXP) Upgraded to Buy: Here's Why [Yahoo! Finance]

Report

11/26

08:16 am

nrxp

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024 [Yahoo! Finance]

Medium Report

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024 [Yahoo! Finance]

Report

11/26

08:03 am

nrxp

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024

Medium Report

NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024

Report

11/25

08:50 am

nrxp

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.

Medium Report

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.

Report

11/25

08:12 am

nrxp

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials" [Yahoo! Finance]

Medium Report

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials" [Yahoo! Finance]

Report

11/25

08:03 am

nrxp

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials"

Medium Report

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials"

Report

11/19

02:08 am

nrxp

NRX Pharmaceuticals Inc (NRXP) Q3 2024 Earnings Call Highlights: Significant Reduction in ... [Yahoo! Finance]

Medium Report

NRX Pharmaceuticals Inc (NRXP) Q3 2024 Earnings Call Highlights: Significant Reduction in ... [Yahoo! Finance]

Report

11/18

04:13 pm

nrxp

NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer [Yahoo! Finance]

Medium Report

NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer [Yahoo! Finance]

Report

11/18

04:05 pm

nrxp

NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer

Medium Report

NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer

Report

11/14

04:17 pm

nrxp

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update [Yahoo! Finance]

Low Report

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update [Yahoo! Finance]

Report

11/14

04:05 pm

nrxp

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update

Low Report

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update

Report

11/13

08:03 am

nrxp

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024

Medium Report

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024

Report

11/7

04:06 pm

nrxp

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024

Low Report

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024

Report

10/31

07:00 am

nrxp

NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule

Medium Report

NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule

Report

10/30

07:52 am

nrxp

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics [Yahoo! Finance]

Medium Report

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics [Yahoo! Finance]

Report

10/30

07:47 am

nrxp

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics

High Report

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics

Report

10/23

08:30 am

nrxp

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024

Medium Report

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024

Report

10/22

05:56 am

nrxp

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.

Medium Report

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.